4D Molecular Therapeutics FDMT Deferred revenue, net of current portion
Deferred revenue, net of current portion at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's deferred revenue, net of current portion.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's deferred revenue, net of current portion?
- 4D Molecular Therapeutics (FDMT) reported deferred revenue, net of current portion of $2.13M in Q1 2026.
- How has 4D Molecular Therapeutics's deferred revenue, net of current portion changed year-over-year?
- 4D Molecular Therapeutics's deferred revenue, net of current portion increased by 389.6% year-over-year, from $434K to $2.13M.
- What is the long-term trend for 4D Molecular Therapeutics's deferred revenue, net of current portion?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's deferred revenue, net of current portion has grown at a -43.7% compound annual growth rate (CAGR), from $13.23M to $745K.